Piet Postmus
Professor Pulmonology
- Name
- Prof.dr. P.E. Postmus
- p.e.postmus@lumc.nl
- ORCID iD
- null
Piet Postmus is head of department and chair of Pulmonary Diseases at LUMC. Awards: 2015 Heine H. Hansen award of ESMO en IASLC 2013 Joseph Cullen prevention /early detection award (IASLC)
More information about Piet Postmus
See also
Pulmonary Diseases
The chair Pulmonary Diseases is connected to head of department with as specific mission to modify the focus of the department towards the main themes of LUMC as described in “Grensverleggend beter worden. Strategie LUMC 2018-2013”.
Within the department the following themes have been selected:
- Oncology (lung cancer is one of the most important causes of death due to cancer)
- Regenerative medicine (both loss of tissue by severe emphysema, as well as disturbed inflammatory responses resulting in fibrosis)
- Applying e-health for care of these patients.
Academic career
During my training (’77-’82) for chest physician I started clnical-scientific researds aiming at new therapeutic approches for lung cancer and defended my Dr. thesis (“New approaches in small cell lung cancer”) on November 13, 1985.
Within the University hospital in Groningen I started the programs for lung cancer and lung transplantation. I moved to Amsterdam to become chair and head of department (1-3-1992). My inaugural lecture was given in 1995 “…dat lossen we samen wel op”.
During these years I participated in clinical research with the themes lung cancer, endoscopy, pneumothorax, pulmonary circulation. A large part of this research has been incorporated in several doctorate theses.
After my emeritus I was invited by the University of Liverpool to try to improve care and research for lung cancer in Liverpool (UK). With mixed success I worked there for 2.5 yrs.
Since 1-10-2017 I’m working in LUMC with the above described tasks. In my inauagaral lecture “Grensverleggend maatwerk” I described in more detail the above mentioned plans.
Professor Pulmonology
- Faculteit Geneeskunde
- Divisie 2
- Longziekten
Contact
- Beek, I. van de; Glykofridis, I.E.; Tanck, M.W.T.; Luijten, M.N.H.; Starink, T.M.; Balk, J.A.; Johannesma, P.C.; Hennekam, E.; Hoff, M.J.B. van den; Gunst, Q.D.; Gille, J.J.P.; Polstra, A.M.; Postmus, P.E.; Steensel, M.A.M. van; Postma, A.V.; Wolthuis, R.M.F.; Menko, F.H.; Houweling, A.C. & Waisfisz, Q. (2023), Familial multiple discoid fibromas is linked to a locus on chromosome 5 including the FNIP1 gene, Journal of Human Genetics 68(4): 273-279.
- Hoppe, B.P.C.; Stoel, B.C. & Postmus, P.E. (2022), Natural Course of Cysts in Birt-Hogg-Dube Syndrome, American Journal of Respiratory and Critical Care Medicine 205(12): 1474-1475.
- Sriram, J.D.; Beek, I. van de; Johannesma, P.C.; Werkum, M.H. van; Wel, T.J.W.T. van der; Wessels, E.M.; Gille, H.J.J.P.; Houweling, A.C.; Postmus, P.E. & Smit, H.J.M. (2022), Birt-Hogg-Dube syndrome in apparent primary spontaneous pneumothorax patients, BMC Pulmonary Medicine 22(1).
- Huyuk, M.; Fiocco, M.; Postmus, P.E.; Cohen, D. & Thusen, J.H. von der (2022), Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer, Histopathology 82(5).
- Hoeijmakers, F.; Schreurs, W.H.; Comans, E.F.I.; Belderbos, J.S.A.; Postmus, P.E.; Tollenaar, R.A.E.M. & Heineman, D.J. (2022), The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era, Journal of Thoracic Oncology 17(11): 1250-1254.
- Dai, L.; Li, Y.H.; Liang, Y.Y.; Zhao, J.; Chen, G.; Yin, J.; Postmus, P.E.; Addeo, A.; Blasberg, J.D.; Onesti, C.E.; Liao, Z.W.; Rao, X.G. & Long, H.D. (2021), High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases, Journal of Thoracic Disease 13(4): 2437-2446.
- Holstein, Y. van; Deudekom, F.J. van; Trompet, S.; Postmus, I.; Boogaard, A.U. den; Elst, M.J.T. van der; Glas, N.A. de; Heemst, D. van; Labots, G.; Altena, M.; Slingerland, M.; Liefers, G.J.; Bos, F. van den; Bol, J.M. van der; Blauw, G.J.; Portielje, J.E.A. & Mooijaart, S.P. (2021), Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment, BMC Geriatrics 21(1).
- Hondelink, L.M.; Huyuk, M.; Postmus, P.E.; Smit, V.T.H.B.M.; Blom, S.; Thusen, J.H. von der & Cohen, D. (2021), Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer, Histopathology 80(4).
- Morgensztern, D.; Dols, M.C.; Aix, S.P.; Postmus, P.E.; Bennouna, J.; Fischer, J.R.; Juan-Vidal, O.; Stewart, D.J.; Ardizzoni, A.; Bhore, R.; Wolfsteiner, M.; Reck, M.; Talbot, D.; Govindan, R.; Ong, T.J. & ABOUND2L Investigators (2021), Nab-paclitaxel plus durvalumab in patients with previously treated advanced stage non-small cell lung cancer (ABOUND.2L+), Frontiers in Oncology 10.
- Smit, R.A.J.; Trompet, S.; Leong, A.; Goodarzi, M.O.; Postmus, I.; Warren, H.; Theusch, E.; Barnes, M.R.; Arsenault, B.J.; Li, X.H.; Feng, Q.P.; Chasman, D.I.; Cupples, L.A.; Hitman, G.A.; Krauss, R.M.; Psaty, B.M.; Rotter, J.I.; Cessie, S. le; Stein, C.M.; Jukema, J.W. & GIST Consortium (2020), Statin-induced LDL cholesterol response and type 2 diabetes, Pharmacogenomics Journal 20(3): 462-470.
- Hurkmans, D.P.; Kuipers, M.E.; Smit, J.; Marion, R. van; Mathijssen, R.H.J.; Postmus, P.E.; Hiemstra, P.S.; Aerts, J.G.J.V.; Thusen, J.H. von der & Burg, S.H. van der (2020), Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients, Cancer Immunology, Immunotherapy 69(5): 771-777.
- Smeltzer, M.P.; Wynes, M.W.; Lantuejoul, S.; Soo, R.; Ramalingam, S.S.; Varella-Garcia, M.; Taylor, M.M.; Richeimer, K.; Wood, K.; Howell, K.E.; Dalurzo, M.L.; Felip, E.; Hollenbeck, G.; Kerr, K.; Kim, E.S.; Mathias, C.; Pacheco, J.; Postmus, P.; Powell, C.; Tsuboi, M.; Wistuba, I.I.; Wakelee, H.A.; Belani, C.P.; Scagliotti, G.V. & Hirsch, F.R. (2020), The international association for the study of lung cancer global survey on molecular testing in lung cancer, Journal of Thoracic Oncology 15(9): 1434-1448.
- Cohen, D.; Hondelink, L.M.; Solleveld-Westerink, N.; Uljee, S.M.; Ruano, D.; Cleton-Jansen, A.M.; Thusen, J.H. von der; Ramai, S.R.S.; Postmus, P.E.; Roggen, J.F.G. van; Hoppe, B.P.C.; Clahsen, P.C.; Maas, K.W.; Ahsmann, E.J.M.; Heuvel, A. ten; Smedts, F.; Rossem, R.N. van & Wezel, T. van (2020), Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing, Journal of Thoracic Oncology 15(6): 1000-1014.
- Westerink, L.; Nicolai, J.L.J.; Samuelsen, C.; Smit, H.J.M.; Postmus, P.E.; Griebsch, I. & Postma, M.J. (2020), Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations, European Journal of Health Economics 21(6): 931-943.
- Aix, S.P.; Talbot, D.; Govindan, R.; Dols, M.C.; Postmus, P.E.; Lewanski, C.; Bennouna, J.; Fischer, J.R.; Juan-Vidal, O.; Stewart, D.J.; Ardizzoni, A.; Bhore, R.; Wolfsteiner, M.; Reck, M.; Ong, T.J. & Morgensztern, D. (2020), Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, Future Oncology 16(12): 749-762.
- Dingemans, A.M.C.; Hendriks, L.E.L.; Berghmans, T.; Levy, A.; Hasan, B.; Faivre-Finn, C.; Giaj-Levra, M.; Giaj-Levra, N.; Girard, N.; Greillier, L.; Lantuejoul, S.; Edwards, J.; O'Brien, M.; Reck, M.; Smit, E.F.; Schil, P. van; Postmus, P.E.; Ramella, S.; Lievens, Y.; Gaga, M.; Peled, N.; Scagliotti, G.V.; Senan, S.; Paz-Ares, L.; Guckenberger, M.; McDonald, F.; Ekman, S.; Cufer, T.; Gietema, H.; Infante, M.; Dziadziuszko, R.; Peters, S.; Porta, R.R.; Vansteenkiste, J.; Dooms, C.; Ruysscher, D. de; Besse, B. & Novello, S. (2019), Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report, Journal of Thoracic Oncology 14(12): 2109-2119.
- Ng-Blichfeldt, J.P.; Jong, T. de; Kortekaas, R.K.; Wu, X.H.; Lindner, M.; Guryev, V.; Hiemstra, P.S.; Stolk, J.; Konigshoff, M. & Gosens, R. (2019), TGF-beta activation impairs fibroblast ability to support adult lung epithelial progenitor cell organoid formation, AJP - Lung Cellular and Molecular Physiology 317(1): L14-L28.
- Hurkmans D, Kuipers M, Smit J, Mathijssen R, Postmus P, Hiemstra P, Aerts J, van Marion R, van der Burg S & von der Thusen J (2019), Combined assessment of tumour mutational load, CD8+T cell infiltration, and expression of PD-L1 and HLA class I in small biopsy specimens to predict immunotherapy response in non-small cell lung cancer, Virchows Archiv 475: S41-S41.
- Thunnissen, E.; Lissenberg-Witte, B.I.; Heuvel, M.M. van den; Monkhorst, K.; Skov, B.G.; Sorensen, J.B.; Mellemgaard, A.; Dingemans, A.M.C.; Speel, E.J.M.; Langen, A.J. de; Hashemi, S.M.S.; Bahce, I.; Drift, M.A. van der; Looijen-Salamon, M.G.; Gosney, J.; Postmus, P.E.; Samii, S.M.S.; Duplaquet, F.; Weynand, B.; Durando, X.; Penault-Llorca, F.; Finn, S.; Grady, A.O.; Oz, B.; Akyurek, N.; Buettner, R.; Wolf, J.; Bubendorf, L.; Duin, S.; Marondel, I.; Heukamp, L.C.; Timens, W.; Schuuring, E.M.D.; Pauwels, P. & Smit, E.F. (2019), ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib, Lung Cancer 138: 13-18.
- Postmus, P.E. (2019), Brain metastases: costs for care need to be spend more effectively!, Annals of palliative medicine 8(2): 207-209.
- Johannesma, P.C.; Beek, I. van de; Wel, T.J.W.T. van der; Reinhard, R.; Rozendaal, L.; Starink, T.M.; Waesberghe, J.H.T.M. van; Horenblas, S.; Gille, H.J.J.P.; Jonker, M.A.; Meijers-Heijboer, H.E.J.; Postmus, P.E.; Houweling, A.C. & Moorselaar, J.R.A. van (2019), Renal imaging in 199 Dutch patients with Birt-Hogg-Dube syndrome: Screening compliance and outcome, PLoS ONE 14(3).
- Cho, B.C.; Obermannova, R.; Bearz, A.; McKeage, M.; Kim, D.W.; Batra, U.; Borra, G.; Orlov, S.; Kim, S.W.; Geater, S.L.; Postmus, P.E.; Laurie, S.A.; Park, K.; Yang, C.T.; Ardizzoni, A.; Bettini, A.C.; Castro, G. de; Kiertsman, F.; Chen, Z.; Lau, Y.Y.; Viraswami-Appanna, K.; Passos, V.Q. & Dziadziuszko, R. (2019), Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study, Journal of Thoracic Oncology 14(7): 1255-1265.
- Morgensztern, D.; Ko, A.; O'Brien, M.; Ong, T.J.; Waqar, S.N.; Socinski, M.A.; Postmus, P.E. & Bhore, R. (2019), Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy, Cancer 125(14): 2394-2399.
- Smeltzer M, Wynes M, Taylor M, Richeimer K, Wood K, Howell K, Dalurzo M, Felip E, Kerr K, Kim E, Lantuejoul S, Mathias C, Postmus P, Powell C, Ramalingam S, Soo R, Tsuboi M, Wistuba I, Varella-Garcia M, Scagliotti G & Hirsch FR (2019), The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer, Journal of Thoracic Oncology 14(10): S335-S336.
- Hurkmans D, Kuipers M, Smit J, Van Marion R, Mathijssen R, Postmus P, Hiemstra P, Aerts J, Von der Thusen J & Van der Burg S (2019), Tumor Mutational Load, CD8+T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions, Journal of Thoracic Oncology 14(10): S726-S726.